McKesson is the largest pharmaceutical distributor in the United States and one of the world's leading healthcare companies.
McKesson Corporation is the largest pharmaceutical distributor in the United States, generating $359.1 billion in revenue in fiscal year 2025 and growing at 16% annually. The company distributes pharmaceuticals to retail chains, independent pharmacies, hospital systems, and specialty providers across the United States, Canada, and Europe. McKesson's oncology platform — including The US Oncology Network of approximately 2,500 physicians and the iKnow Oncology data platform — is the most strategically differentiated asset in the pharmaceutical distribution industry, positioning McKesson as an indispensable partner to oncology drug manufacturers. The company announced its intent to separate its Medical-Surgical Solutions segment in 2025, sharpening focus on pharmaceutical distribution and oncology.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and digital health platforms
• Latest products, programs, and service initiatives
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Technological Know-How and Key Products
7. M&A and Partnerships
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. McKesson — Key Financial Metrics 2023-2025
Table 2. McKesson — Revenue by Segment 2023-2025
Table 3. McKesson — Membership and Covered Lives 2023-2025
Table 4. McKesson — R&D and Technology Investment 2023-2025
Table 5. McKesson — SWOT Analysis
Table 6. McKesson — Key Products and Programs 2025
Table 7. McKesson — M&A Activity 2020-2025
Table 8. McKesson — Key Management 2025
Table 9. McKesson — Strategic Priorities 2025-2030
